Core Viewpoint - A class action lawsuit has been announced by Rosen Law Firm on behalf of purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc, covering the period from June 5, 2023, to December 26, 2025, due to alleged misleading statements regarding the company's clinical studies [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma provided investors with optimistic information about the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI), suggesting confidence in the drug's ability to reduce annualized fracture rates [5]. - It is alleged that while making these positive statements, Mereo BioPharma concealed material adverse facts about the Phase 3 programs, which ultimately did not meet their primary endpoints [6]. - The misleading statements led to investors purchasing Mereo's ADSs at artificially inflated prices, resulting in damages when the true information became public [6]. Group 2: Participation Information - Investors who purchased Mereo ADSs during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][7].

Core Viewpoint - Mereo BioPharma Group plc is facing potential legal claims due to alleged violations of federal securities laws related to misleading statements about its Phase 3 clinical trials, which failed to meet primary endpoints [4][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is investigating claims against Mereo BioPharma and has set an April 6, 2026 deadline for investors to seek the role of lead plaintiff in a federal securities class action [2]. - The firm encourages investors who suffered losses in Mereo to contact them directly to discuss their legal options [1][8]. Group 2: Clinical Trial Results - Mereo announced that two Phase 3 studies of setrusumab did not meet their primary endpoints of reducing annualized clinical fracture rates compared to placebo and bisphosphonates [5]. - Despite the primary endpoint failures, the trials showed statistically significant improvements in bone mineral density on secondary endpoints, and no new safety concerns were identified [5]. Group 3: Market Reaction - Following the announcement of the failed trials, Mereo's stock price dropped by $2.02 per share, a decline of 87.64%, closing at $0.28 per share on December 29, 2025 [6].

NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of American Depositary Shares (“ADS”) of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2026. SO WHAT: If you purchased Mereo ADSs during the Class Pe ...

Core Insights - Spark Energy Minerals Inc. has reported promising results from its maiden Reverse Circulation drill program at the Arapaima Project in Brazil's Lithium Valley, indicating a laterally continuous critical minerals system [1][9]. Rare Earth Elements (REE) Highlights - All five drill holes intersected broad rare earth mineralization, with Magnet Rare Earth Oxides (MREO) comprising up to 33% of Total Rare Earth Oxides (TREO) [2][3][4]. - The consistent mineralization across all holes suggests a coherent and laterally continuous mineralized system rather than isolated high-grade zones [3][8]. Gallium Mineralization - Gallium was intersected from surface in all five holes, highlighting the near-surface character of the system and its strategic importance in advanced technologies [5][12]. - The presence of gallium is significant due to its critical role in semiconductors and other high-tech applications, with global supply being highly concentrated [5][20]. Geological Interpretation - The drilling results support the interpretation of a coherent and vertically developed supergene mineralized system formed through deep tropical weathering of granitic host rocks [9][10]. - The average spacing of approximately 380 meters between drill holes strengthens the interpretation of a laterally continuous mineralized system across a meaningful footprint [7][8]. Strategic Importance of the Arapaima Project - The Arapaima Project is located in Brazil's Lithium Valley, a region gaining international recognition for lithium and critical mineral discoveries, which aligns with global supply chain diversification efforts [17][18]. - As demand for magnet rare earths and gallium intensifies, Brazil's Lithium Valley continues to attract international attention as a prospective critical minerals district [20].

NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Mereo BioPharma Group PLC (NASDAQ: MREO) (“Mereo” or the “Company”) inclusive on behalf of all persons and entities that purchased or otherwise acquired Mereo American Depositary Shares (“ADS’s”) between June 5, 2023 and December 26, 2025, both dates inclusive (the "Class Period"). Investors have until April 6, 2026, to seek appointments as lead plaintiff. PLEASE ...

New York, New York--(Newsfile Corp. - February 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023, and December 26, 2025. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2026.SO WHAT: If you purchased Mereo ADSs during the Class Period you may be e ...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors are advised to contact Danielle Peyton at [[email protected]] or 646-581-9980, (or 888.4-POMLAW), toll-f ...

Mereo BioPharma Group plc Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your Rights - MREO [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Mereo BioPharma Group plc (NASDAQ: MREO).Shareholders who purchased shares of MREO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment ...

LOS ANGELES, Feb. 12, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Mereo BioPharma Group plc, (“Mereo” or the "Company") (NASDAQ: MREO) investors of a class action on behalf of investors that bought securities between June 5, 2023 and December 26, 2025, inclusive (the “Class Period”). Mereo investors have until April 6, 2026 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal r ...

Core Viewpoint - Mereo BioPharma Group plc is facing a securities class action lawsuit due to alleged violations of federal securities laws related to misleading statements about its Phase 3 clinical trials, which failed to meet primary endpoints [1][1]. Group 1: Legal Action and Deadlines - Faruqi & Faruqi, LLP is investigating claims against Mereo BioPharma and reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in the class action [1]. - The lawsuit alleges that Mereo and its executives made false or misleading statements regarding the Phase 3 ORBIT and COSMIC programs [1][1]. Group 2: Clinical Trial Results - Mereo announced on December 29, 2025, that two Phase 3 studies of setrusumab did not meet their primary endpoints of reducing annualized clinical fracture rates compared to placebo and bisphosphonates [1][1]. - Despite showing statistically significant improvements in bone mineral density on secondary endpoints, the failure to meet primary endpoints led to a negative market reaction [1]. Group 3: Stock Price Impact - Following the announcement of the failed trials, Mereo's stock price dropped by $2.02 per share, representing an 87.64% decline, closing at $0.28 per share on December 29, 2025 [1][1].